Real-world data from Tokyo confirm that pembrolizumab combined with chemotherapy before and after surgery delivers event-free survival outcomes close to those reported in the KEYNOTE-522 trial setting for early-stage triple-negative disease and estrogen receptor-low tumors. The multicenter analysis followed 95 patients and used outcomes to benchmark effectiveness in practice. The report underscores that translation of trial results into routine oncology workflows is possible at the population level, not only in controlled trials. This type of evidence is especially useful as treatment patterns evolve toward biomarker-informed sequencing. For clinicians and planners, the key operational signal is the durability of benefit when care pathways and scheduling differ from pivotal trial protocols.